Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III

Portal vein thrombosis is a major complication associated with liver cirrhosis. In cirrhotic patients, a decrease in procoagulant and anticoagulant factors and an unstable balance between them is observed, and a relative decrease in the activation of anticoagulant drivers is one of the main causes o...

Full description

Bibliographic Details
Main Authors: Satoshi Nakayama, Naoya Murashima
Format: Article
Language:English
Published: Hindawi Limited 2020-01-01
Series:Case Reports in Medicine
Online Access:http://dx.doi.org/10.1155/2020/8268016
id doaj-a0417fb7b7f642b6b64efd4f57372b0d
record_format Article
spelling doaj-a0417fb7b7f642b6b64efd4f57372b0d2020-11-25T03:27:59ZengHindawi LimitedCase Reports in Medicine1687-96271687-96352020-01-01202010.1155/2020/82680168268016Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin IIISatoshi Nakayama0Naoya Murashima1Department of Gastroenterology, Mishuku Hospital, 5-33-12, Kamimeguro, Meguro-ku, Tokyo 153-0051, JapanDepartment of Gastroenterology, Mishuku Hospital, 5-33-12, Kamimeguro, Meguro-ku, Tokyo 153-0051, JapanPortal vein thrombosis is a major complication associated with liver cirrhosis. In cirrhotic patients, a decrease in procoagulant and anticoagulant factors and an unstable balance between them is observed, and a relative decrease in the activation of anticoagulant drivers is one of the main causes of portal vein thrombosis (PVT). Herein, we report a case of acute portal thrombosis associated with liver cirrhosis and treated with a recombinant form of soluble thrombomodulin (thrombomodulin alpha, TM-α) in combination with antithrombin III. TM-α was administered in accordance with the dosage and route of administration for disseminated intravascular coagulation therapy and resulted in dissolution of PVT with a gradual decrease in D-dimer levels. No adverse events were observed during the course of treatment. In the future, in addition to conventional anticoagulation therapy using heparin or antivitamin K drugs, novel therapies targeting protein C activation using a recombinant form of soluble thrombomodulin may play an important role in the treatment of acute PVT.http://dx.doi.org/10.1155/2020/8268016
collection DOAJ
language English
format Article
sources DOAJ
author Satoshi Nakayama
Naoya Murashima
spellingShingle Satoshi Nakayama
Naoya Murashima
Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III
Case Reports in Medicine
author_facet Satoshi Nakayama
Naoya Murashima
author_sort Satoshi Nakayama
title Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III
title_short Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III
title_full Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III
title_fullStr Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III
title_full_unstemmed Acute Portal Vein Thrombosis Treated with Recombinant Human Soluble Thrombomodulin Combined with Antithrombin III
title_sort acute portal vein thrombosis treated with recombinant human soluble thrombomodulin combined with antithrombin iii
publisher Hindawi Limited
series Case Reports in Medicine
issn 1687-9627
1687-9635
publishDate 2020-01-01
description Portal vein thrombosis is a major complication associated with liver cirrhosis. In cirrhotic patients, a decrease in procoagulant and anticoagulant factors and an unstable balance between them is observed, and a relative decrease in the activation of anticoagulant drivers is one of the main causes of portal vein thrombosis (PVT). Herein, we report a case of acute portal thrombosis associated with liver cirrhosis and treated with a recombinant form of soluble thrombomodulin (thrombomodulin alpha, TM-α) in combination with antithrombin III. TM-α was administered in accordance with the dosage and route of administration for disseminated intravascular coagulation therapy and resulted in dissolution of PVT with a gradual decrease in D-dimer levels. No adverse events were observed during the course of treatment. In the future, in addition to conventional anticoagulation therapy using heparin or antivitamin K drugs, novel therapies targeting protein C activation using a recombinant form of soluble thrombomodulin may play an important role in the treatment of acute PVT.
url http://dx.doi.org/10.1155/2020/8268016
work_keys_str_mv AT satoshinakayama acuteportalveinthrombosistreatedwithrecombinanthumansolublethrombomodulincombinedwithantithrombiniii
AT naoyamurashima acuteportalveinthrombosistreatedwithrecombinanthumansolublethrombomodulincombinedwithantithrombiniii
_version_ 1715207125306703872